Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA): 86 pipeline candidates · 5 upcoming catalysts · ~505 mo cash runway · 30 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
504.9 months
D/E 3.87
Lead: Approved
86 candidates
5 upcoming, next in ~93d
0 buys · 35 sells (180d)
A transparent, data-derived signal for Teva Pharmaceutical Industries Limitedacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$37.9B
Cash
$3.7B
Quarterly Burn
$40.0M
Runway
504.9 mo
Revenue
$4.0B
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (86 candidates)
| Drug | Phase |
|---|---|
| abs | Phase 3 |
| acamprosate | Approved |
| airduo respiclick | Approved |
| albuterol emdpi ds | Phase 4 |
| alendronate | Approved |
| amlodipine | Approved |
| argatroban in 0.9% | Approved |
| atomoxetine | Approved |
| atorvastatin | Approved |
| austedo xr | Approved |
Showing 10 of 86 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
648
Total value held
$14.77B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 65,136,464 | $1.96B |
| menora mivtachim holdings ltd. | 39,626,383 | $1.19B |
| wcm investment management, llc | 40,820,600 | $1.16B |
| fmr llc | 33,132,795 | $998.0M |
| state street corp | 17,790,020 | $535.8M |
| rubric capital management lp | 15,250,000 | $459.3M |
| susquehanna international group, llp | 13,195,215 | $397.4M |
| altshuler shaham ltd | 11,468,401 | $335.9M |
| geode capital management, llc | 10,564,988 | $316.3M |
| janus henderson group plc | 9,633,314 | $290.2M |
Showing top 10 of 648 institutional holders of Teva Pharmaceutical Industries Limited. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Teva Pharmaceutical Industries Limited's pipeline?
Teva Pharmaceutical Industries Limited (TEVA) has 86 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Teva Pharmaceutical Industries Limited's lead drug candidate?
Teva Pharmaceutical Industries Limited's most advanced tracked candidate is abs (Phase 3) for Asthma.
What is Teva Pharmaceutical Industries Limited's next catalyst?
Teva Pharmaceutical Industries Limited's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone" — expected September 19, 2026.
What is Teva Pharmaceutical Industries Limited's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Teva Pharmaceutical Industries Limited has approximately 504.9 months of cash runway.
What is Teva Pharmaceutical Industries Limited's market capitalization?
Teva Pharmaceutical Industries Limited's market capitalization is approximately $37.9B.
Get the full picture on Teva Pharmaceutical Industries Limited
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.